Alnylam Pharma's market cap is currently $52.92B. The company's EPS TTM is $1.84; its P/E ratio is 1,665.45; Alnylam Pharma is scheduled to report earnings on October 30, 2025, and the estimated EPS forecast is $1.27. See an overview of income statement, balance sheet, and cash flow financials.
